Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2968363 | 0.91 | RXRA (0.53) | NPSR1CA2ALDH1A1LMNARXRA | |
| SCHEMBL17789991 | 0.84 | MTNR1A (0.47) | NPSR1MTNR1AMTNR1BACHETAAR1 | |
| SCHEMBL25179436 | 0.83 | MTNR1B (0.54) | MTNR1AMTNR1BACHECES2CES1 | |
| SCHEMBL3876533 | 0.83 | MTNR1A (0.50) | NPSR1MTNR1AMTNR1BACHETAAR1 | |
| SCHEMBL4572866 | 0.83 | MTNR1A (0.50) | NPSR1MTNR1AMTNR1BACHETAAR1 | |
| SCHEMBL30333595 | 0.83 | MTNR1B (0.54) | MTNR1AMTNR1BACHECES2CES1 | |
| SCHEMBL13791773 | 0.83 | MTNR1A (0.50) | NPSR1MTNR1AMTNR1BACHETAAR1 | |
| SCHEMBL11578736 | 0.83 | TAAR1 (0.56) | NPSR1MTNR1AMTNR1BACHETAAR1 | |
| 1,3-Dimethoxybenzene SCHEMBL9350 | 0.83 | ACHE (0.70) | ACHETAAR1CES2CES1CA1 | |
| 1,3-Dimethoxybenzene SCHEMBL901285 | 0.83 | ACHE (0.70) | ACHETAAR1CES2CES1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088797-B2 | Substituted N-(4-cyano-1H-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | claimed |
| US-20100041709-A1 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | claimed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| EP-0389162-B1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES (JP) | 1993-12-08 | — | — | EP | disclosed |
| US-5086071-A | Improved chemical stability and ppotent in vivo | TORAY INDUSTRIES, INC. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0232776-B1 | 2,5,6,7-TETRANOR-4,8-INTER-M-PHENYLENE PGI2 DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0389162-A1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1990-09-26 | — | — | EP | disclosed |
| EP-0365678-A1 | 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1990-05-02 | — | — | EP | disclosed |
| US-4775692-A | ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT | TORAY INDUSTRIES, INC. (JP) | 1988-10-04 | — | — | US | disclosed |
| EP-0232776-A2 | 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1987-08-19 | — | — | EP | disclosed |
| US-4031082-A | Process for preparing 3-acycloxymethyl-2-cephem compounds | ELI LILLY AND COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
| US-4029651-A | ESTERIFICATION | ELI LILLY AND COMPANY (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | NPSR1 1184/4885MTNR1A 103/4885MTNR1B 93/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NPSR1 1134/4885MTNR1A 106/4885MTNR1B 93/4885 |
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | AIFM2, FABP7, FASN | NPSR1 3693/4885MTNR1A 3425/4885MTNR1B 3351/4885 |
| US-20100041709-A1 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT3, PRMT5, PRMT1 | NPSR1 66/4885MTNR1A 45/4885MTNR1B 56/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NPSR1 688/4885MTNR1A 54/4885MTNR1B 53/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NPSR1 688/4885MTNR1A 54/4885MTNR1B 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.